Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Size: px
Start display at page:

Download "Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404"

Transcription

1 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description, is a lyophilized concentrate of purified von Willebrand factor (VWF) and blood clotting factor VIII as well as other plasma proteins including fibrinogen and albumin was originally approved by the Food and Drug Administration for use in adult patients to treat and prevent bleeding from hemophilia A. Later the approval was expanded to treat spontaneous and traumatic bleeding for severe Von Willebrand s disease (VWD) and for mild and moderate VWD when desmopressin use is known or suspected to be inadequate. Policy/Criteria I. It is the policy of Health Net of California that is considered medically necessary in adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia). II. It is the policy of Health Net of California that is considered medically necessary in adult and pediatric patients with severe VWD and either of the following indications: A. Treatment of spontaneous and trauma-induced bleeding episodes; B. Prevention of excessive bleeding during and post- surgery. III. It is the policy of Health Net of California that is considered medically necessary in adult and pediatric patients with mild to moderate VWD when the use of desmospressin is known or suspected to be inadequate or contraindicated and meet either of the following indications: A. Treatment of spontaneous and trauma-induced bleeding; B. Prevention of excessive bleeding during and post- surgery. Background Inherited bleeding disorders include abnormalities of coagulation factors and platelet function. Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is the most common type of hemophilia. Hemophilia A is a genetic disorder caused by missing or defective factor VIII. Treatment of hemophilia A is replacement therapy with clotting factor VIII. Desmopressin, the synthetic version of a natural hormone vasopressin, is used to treat people with mild to moderate hemophilia A. Desmopressin stimulates the release of stored factor VIII and VWF and increases the level of these proteins in the blood. VWF, a clotting protein, carries and binds factor VIII, which then can stay in the bloodstream longer. Page 1 of 5

2 VWD is an inherited bleeding disorder that is caused by deficiency or dysfunction of VWF, a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and also binds and stabilizes blood clotting factor VIII (FVIII) in the circulation. Therefore, defects in VWF can cause bleeding by impairing platelet adhesion or by reducing the concentration of FVIII.. VWD is the most common bleeding disorder, affecting up to 1% of the US population. Treatment for VWD depends on the diagnosis and severity. The mainstay of treatment is Desmopressin, which stimulates the release of VWF from cells, which also increases FVIII. Desmopressin is effective in almost all patients with mild or moderate type 1 disease. In comparison, a high proportion of those with severe bleeding symptoms and marked prolongation of the bleeding time do not respond sufficiently to desmopressin. Desmopressin is also ineffective in the rare patients with type 1 disease who have normal or decreased levels of plasma VWF accompanied by absent stores of VWF in platelets. Desmopressin can be used to treat bleeding complications or to prepare patients with VWD for surgery. Patients with type 3 VWD and those with more severe type 2 disease often require replacement therapy with VWF. Replacement therapy is also indicated in some patients with type 1 VWD who have a more severe decrease of VWF, particularly in more serious bleeding situations when other measures have failed, or in those who may need prolonged treatment (e.g, post-surgery)., is purified from pooled human plasma from many donors and contains the clotting proteins deficient or defective in VWD, factor VIII and VWF. It is pasteurized by heat treatment and administered by the intravenous route. The FDA based its approval of use of in patients with VWD on results from two clinical trials - a U.S. clinical study of 35 VWD patients undergoing surgery and another study in Europe of an additional 27 subjects. Across the studies, 44 of the 62 patients underwent surgeries that could be classified as major (including joint replacement, intracranial surgery, and hysterectomy). In 61 subjects, investigators classified the efficacy of as either good or excellent. 1 National Heart, Lung and Blood Institute Humate- P is indicated for use in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding when use of DDAVP is thought or known to be inadequate or contraindicated. has received FDA approval for use in prophylactic management of surgery and invasive procedures in patients with VWD. 2 Coding Implications This clinical policy references Current Procedural Terminology (CPT ). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2015, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. Page 2 of 5

3 CPT Description Codes Home infusion/specialty drug administration, per visit (up to 2 hours) Home infusion/specialty drug administration, each additional hour HCPCS Codes J7187 S9345 Description Injection, von Willebrand Factor Complex, (), per Iu VWF-RCO Home infusion therapy, anti-hemophilic agent infusion therapy (e.g., factor VIII); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem ICD-10-CM Diagnosis Codes that Support Coverage Criteria ICD-10-CM Description Code D66 Hereditary factor VIII deficiency D68.0 Von Willebrand s disease Reviews, Revisions, and Approvals Date Approval Date Policy adopted from Health Net NMP 404 (Antihemophiliac Factor/von Willebrand Factor Complex Human) 12/16 12/16 References 1. U.S. Food and Drug Administration. Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.. Oct National Heart, Lung and Blood Institute. The Diagnosis, Evaluation and Management of von Willebrand Disease. Aug Available at: 3. Mannuccio Mannucci P, Kyrle PA, Schulman S, Di Paola J, et al.. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus Oct;11(4): Auerswald G, Kreuz W. Haemate P/ for the treatment of von Willebrand disease: considerations for use and clinical experience. Haemophilia Nov;14 Suppl 5: Berntorp E. Haemate P/: a systematic review. Thromb Res Nov;124 Suppl 1:S Carter NJ, Scott LJ. Human plasma von Willebrand factor/factor VIII complex (Haemate P/): in von Willebrand disease and haemophilia A. Drugs. 2007;67(10): Page 3 of 5

4 7. Eckhardt CL, Mauser-Bunschoten EP, Peters M, et al. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. Br J Haematol Jun;157(6): Castaman G, Coppola A, Zanon E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia Sep Rothschild C, D'oiron R, Borel-Derlon A, et al. Use of Haemate P as immune tolerance induction in patients with severe haemophilia A, who have failed previous induction attempts: a multicentre observational study. Haemophilia Oct Furlong B, Furlong M. Hemophilia, Type A. emedicine. Last updated January Available at: Geil J. Von Willebrand Disease. emedicine. Last updated February Available at: Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. Health Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan s affiliates, as applicable. The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures. This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time. Page 4 of 5

5 This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan. This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy. Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at for additional information Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 5 of 5

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (NovoSeven RT) Reference Number: CP.PHAR.220 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.CPA.262 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.CPA.262 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Leukine) Reference Number: CP.CPA.262 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lumoxiti) Reference Number: CP.PHAR.398 Effective Date: 10.16.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Kymriah) Reference Number: CP.CPA.XX Effective Date: 09.26.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Filgrastim, Filgrastim-sndz, Tbo-filgrastim Reference Number: CP.PHAR.297

Clinical Policy: Filgrastim, Filgrastim-sndz, Tbo-filgrastim Reference Number: CP.PHAR.297 Clinical Policy: Reference Number: CP.PHAR.297 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pegfilgrastim (Neulasta), Pegfilgrastim-jmdb (Fulphila) Reference Number: CP.PHAR.296 Effective Date: 12.01.16 Last Review Date: 02.19 Line of Business: Commercial, HIM*, Medicaid Coding

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Policy: Erythropoiesis Stimulating Agents (ESAs) Reference Number: TCHP.PHAR.1813 Effective Date: 07.01.18 Last Review Date: 04.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Betaseron, Extavia) Reference Number: CP.PHAR.256 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at

More information

Clinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18

Clinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18 Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 04.01.17 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18

Clinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18 Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Betaseron, Extavia) Reference Number: CP.CPA.331 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

Prior Authorization Criteria Hemophilia/Blood Factor Products

Prior Authorization Criteria Hemophilia/Blood Factor Products Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Arixtra) Reference Number: CP.PHAR.226 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at

More information

Clotting Disorder Therapy

Clotting Disorder Therapy Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Clinical Policy: Eculizumab (Soliris) Reference Number: CP.PHAR.97

Clinical Policy: Eculizumab (Soliris) Reference Number: CP.PHAR.97 Clinical Policy: (Soliris) Reference Number: CP.PHAR.97 Effective Date: 03/12 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Synagis) Reference Number: CP.PHAR.16 Effective Date: 08.01.09 Last Review Date: 05.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

Clinical Policy: Palivizumab (Synagis) Reference Number: ERX.SPA.124 Effective Date: Last Review Date: 08.17

Clinical Policy: Palivizumab (Synagis) Reference Number: ERX.SPA.124 Effective Date: Last Review Date: 08.17 Clinical Policy: (Synagis) Reference Number: ERX.SPA.124 Effective Date: 10.01.16 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Plasma City. A place where you can build your future with ALPHANATE

Plasma City. A place where you can build your future with ALPHANATE Welcome to Plasma City A place where you can build your future with ALPHANATE A plasma-derived treatment for patients with hemophilia A and von Willebrand disease Please see Important Safety Information

More information

Clinical Policy: Octreotide Acetate (Sandostatin Injection, Sandostatin LAR Depot) Reference Number: CP.PHAR.40

Clinical Policy: Octreotide Acetate (Sandostatin Injection, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Clinical Policy: (Sandostatin Injection, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03/10 Last Review Date: 03/17 See Important Reminder at the end of this policy for important

More information

Clinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95

Clinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95 Clinical Policy: (Thalomid) Reference Number: ERX.SPMN.95 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS

CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS Protocol: PHA027 Effective Date: February 1, 2019 Table of Contents Page BENEFIT CONSIDERATIONS... 1 COVERAGE RATIONALE... 2 US FOOD AND DRUG

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis CADTH TECHNOLOGY REVIEW Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 2 Publication

More information

Common Inherited Bleeding Disorders

Common Inherited Bleeding Disorders CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Synagis) Reference Number: CP.HNMC.159 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Arixtra) Reference Number: CP.PHAR.226 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See

More information

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018 Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested

More information

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: 2018D0047K Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...

More information

Clinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225

Clinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225 Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone #

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone # Hemophilia Product Prior Authorization Form Please complete this form in its entirety and provide relevant progress notes and/or bleeding diaries and fax to 1-888-656-0841 or call 1-800-424-7892. All lab

More information

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated) Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders

More information

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: PHA027 Effective Date: November 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...

More information

Clinical Policy: Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328

Clinical Policy: Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328 Clinical Policy: (Strensiq) Reference Number: CP.PHAR.328 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia Corporate News Baxter International Inc. One Baxter Parkway Deerfield, IL 60015 BAXTER MEDIA CONTACT: BAXTER INVESTOR RELATIONS: Marie Kennedy Mary Kay Ladone (805) 372-3543 (847) 948-3371 Doreen Eaton

More information

Introduction KEY POLICY IMPLICATIONS SUMMARY A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS HEMOPHILIA A

Introduction KEY POLICY IMPLICATIONS SUMMARY A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS HEMOPHILIA A A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS APRIL 2018 Introduction HEMOPHILIA A Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood

More information

CLOTTING FACTOR REPLACEMENT THERAPY

CLOTTING FACTOR REPLACEMENT THERAPY CLOTTING FACTOR REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

Antihemophilic Products

Antihemophilic Products Antihemophilic Products Factor VIII Only Advate Alphanate Eloctate Helixate FS Hemofil M Humate - P Koate - DVI Kogenate FS with Vial Adapter Kogenate FS with Bioset Monoclate - P NovoEight Recombinate

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

AUSTRALIAN BLEEDING DISORDERS REGISTRY

AUSTRALIAN BLEEDING DISORDERS REGISTRY AUSTRALIAN BLEEDING DISORDERS REGISTRY Annual Report 2013-14 With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 6 No 80 ISSN 75 876 The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital Paul Harper, Mary Brasser, Louise

More information

Billing and Coding Guide. Physician Office

Billing and Coding Guide. Physician Office Billing and Coding Guide Physician Office Coverage, coding, and payment in the physician office ONPATTRO (patisiran) received US Food and Drug Administration (FDA) approval on 10 Aug 2018, and is indicated

More information

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3. Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of

More information

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now?

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now? News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,

More information

Clinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

STANDARD BLOOD PRODUCTS AND SERVICES

STANDARD BLOOD PRODUCTS AND SERVICES STANDARD BLOOD PRODUCTS AND SERVICES Policy NHP reimburses contracted providers for the medically necessary administration (transfusion) of blood and standard blood products. Prerequisites Authorization,

More information

DOWNLOAD : STATISTICS OF HEMOPHILIA

DOWNLOAD : STATISTICS OF HEMOPHILIA DOWNLOAD : STATISTICS OF HEMOPHILIA DATA & STATISTICS HEMOPHILIA NCBDDD CDC hemophilia is an inherited bleeding disorder in which the blood does not clot properly. the mission of cdcâ s division of blood

More information

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK Drug Class Insight HEMOPHILIA Background, new developments, key strategies INTRODUCTION Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. 20,000 patients in the

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hemlibra (emicizumab-kxwh) Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hemlibra (emicizumab-kxwh) Prime Therapeutics will review Prior Authorization

More information

Off-Label Use of FDA-Approved Drugs and Biologicals

Off-Label Use of FDA-Approved Drugs and Biologicals Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician

More information

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Personalized hemophilia treatment Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Evolution of Hemophilia

More information

Thriving Amid The Turbulent Ride

Thriving Amid The Turbulent Ride Thursday, April 3 7:00 8:45 AM Rosen Shingle Creek Panzacola F 1/2 A Symposium Held in Conjunction with the 2014 NHIA Annual Conference & Exposition 2014 NHIA Annual Conference & Exposition Thriving Amid

More information

Media Release. Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A. Basel, 17 April 2017

Media Release. Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A. Basel, 17 April 2017 Media Release Basel, 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children

More information

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,

More information

Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852 Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable

More information

Laboratory Tests Chronic Renal Deficiency (CRD) Patients (NCD )

Laboratory Tests Chronic Renal Deficiency (CRD) Patients (NCD ) Policy Number 190.10 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 03/26/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare

More information

Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010

Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 The American Plasma Users Coalition (A-PLUS) is a coalition of national patient advocacy organizations

More information

Current and Emerging Treatment Paradigms in the Management of Hemophilia

Current and Emerging Treatment Paradigms in the Management of Hemophilia Current and Emerging Treatment Paradigms in the Management of Hemophilia Barbara A. Konkle, MD Associate Director, Washington Center for Bleeding Disorders Director, Clinical and Translational Research

More information

RE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress

RE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress March 2, 2009 The Honorable Max Baucus United States Senate Washington, DC 20510 The Honorable Kent Conrad United States Senate Washington, DC 20510 RE: Comparative Clinical Effectiveness Research Comments

More information

Plasma derived medicines - the evidence for their necessity

Plasma derived medicines - the evidence for their necessity Plasma derived medicines - the evidence for their necessity FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES ALBERT FARRUGIA PHD Disclosures I provide compensated services for the manufacturers of therapies

More information

Hemophilia Care. Will there always be new people in the world with. Will hemophilia be treated more effectively and safely

Hemophilia Care. Will there always be new people in the world with. Will hemophilia be treated more effectively and safely Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the

More information

Media Release. CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors

Media Release. CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors Media Release CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors First medicine to significantly reduce treated bleeds compared to prior

More information

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course How to Approach a Patient with Bleeding Nigel Key MB ChB FRCP November 1, 2016 Disclosures for Nigel Key In compliance with COI policy, ISTH requires the following disclosures to the session audience:

More information

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular

More information

EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK

EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK Disclosure Consultancy: CSL Behring, NovoNordisk Travel and honoraria to give lectures: Baxter, Bayer, Biogen, Biotest, Octapharma,

More information

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection.

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. Biostate Malaysia NAME OF THE MEDICINE Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. DESCRIPTION Biostate is a high purity, sterile, powder for injection

More information

Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling

Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Presentation title Date 1 Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Marianne Bork Samuelsen, Msc Pharm Regulatory Affairs Novo Nordisk

More information

Cpt code for ivig infusion 2017

Cpt code for ivig infusion 2017 Cerca Cpt code for ivig infusion 2017 May 26, 2017. The provider bills the per diem charge for five days of IVIG therapy on. Nursing services (CPT codes 99601 and 99602) are covered and do. patients in

More information

Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A

Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A Media Release Basel, 20 November 2017 Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison

More information

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of

More information

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants

More information

Physician Office Billing & Payment Guide

Physician Office Billing & Payment Guide Physician Office Billing & Payment Guide Dermal Regeneration Matrix Dermal Repair Scaffold Ag Antimicrobial Dermal Repair Scaffold Physician Office Billing & Payment Guide Billing and Medicare Payment

More information

LABORATORY APPROCH TO THE BLEEDING PATIENT

LABORATORY APPROCH TO THE BLEEDING PATIENT Anne Winkler, MD Emory University School of Medicine, Atlanta Georgia Assistant Professor, Pathology & Laboratory Medicine Medical Director, Transfusion Service, Grady Health System Assistant Director,

More information

Patients Perspective in Plasma Products (Focus on Hemophilia)

Patients Perspective in Plasma Products (Focus on Hemophilia) Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,

More information

Patients Perspective in Plasma Products (Focus on Hemophilia)

Patients Perspective in Plasma Products (Focus on Hemophilia) Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,

More information

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 International Society Laboratory Hematology Milan, 12-14 May 2016 Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 Augusto B. FEDERICI Hematology and Transfusion Medicine

More information

Cost Assessment of Implementation of Immune Tolerance Induction in Iran

Cost Assessment of Implementation of Immune Tolerance Induction in Iran VALUE IN HEALTH REGIONAL ISSUES 1 (2012) 54 58 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vhri Cost Assessment of Implementation of Immune Tolerance Induction in

More information

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency

More information

Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD

Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD Registry for haemophiliacs in France : FranceCoag Network Thierry Lambert, MD Haemophilia Treatment Center,, Bicêtre History Before 1994: nothing 1994: set up of "Suivi" thérapeutique National des Hémophiles"

More information

Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Media Release Basel, 26 June 2017 Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful

More information

A Review of Coagulation Factor Disorders

A Review of Coagulation Factor Disorders A Review of Coagulation Factor Disorders By Amy Ehlers, BS, PharmD, BCPS Until better treatments or a cure can be found, coagulation factor replacement therapies continue to improve the long-term outcome

More information

UNCLASSIFIED J-CODE CODING AND BILLING US/ULT-PNH/0002

UNCLASSIFIED J-CODE CODING AND BILLING US/ULT-PNH/0002 UNCLASSIFIED J-CODE CODING AND BILLING UNCLASSIFIED/MISCELLANEOUS CODES Used when no existing national code adequately describes the item or service being billed Allows suppliers to begin billing immediately

More information

COVERAGE ELIGIBILITY OF SERVICES ASSOCIATED WITH A CLINICAL TRIAL

COVERAGE ELIGIBILITY OF SERVICES ASSOCIATED WITH A CLINICAL TRIAL Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its

More information

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection.

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. Biostate Singapore NAME OF THE MEDICINE Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. DESCRIPTION Biostate is a high purity, sterile, powder for injection

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA

More information

FDA grants Priority Review to Roche s Hemlibra for people with haemophilia A without factor VIII inhibitors

FDA grants Priority Review to Roche s Hemlibra for people with haemophilia A without factor VIII inhibitors Media Release Basel, 5 June 2018 FDA grants Priority Review to Roche s Hemlibra for people with haemophilia A without factor VIII inhibitors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the

More information

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta

Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta Research Article Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta Umi Nafisah 1, Satibi 2*, DiahAyu Puspandari 3 1) Student at Magister Management Faculty of Pharmacy, UniversitasGadjahMada,

More information

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help

More information

Фармакоэкономика. теория и практика. Pharmacoeconomics. theory and practice

Фармакоэкономика. теория и практика. Pharmacoeconomics. theory and practice 4 Фармакоэкономика теория и практика Pharmacoeconomics theory and practice АНАЛИЗ ФАРМАКОЭКОНОМИЧЕСКИХ И КЛИНИКО-ЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЙ, ОПУБЛИКОВАННЫХ НА БАЗЕ НАУЧНОЙ ЭЛЕКТРОННОЙ БИБЛИОТЕКИ «ELIBRARY.RU»

More information

CMS , Medicare Benefit Policy Manual, Chapter 15- Section 50 - Drugs and Biologicals:

CMS , Medicare Benefit Policy Manual, Chapter 15- Section 50 - Drugs and Biologicals: Billing and Coding Guidelines for Drugs and Biologics (Non-chemotherapy) L 34741 Medicare Excerpts: CMS 100-02, Medicare Benefit Policy Manual, Chapter 15- Section 50 - Drugs and Biologicals: 50.2 - Determining

More information

trial. Key trial data points:

trial. Key trial data points: February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015

More information

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable

More information

Guideline on core SmPC for human fibrinogen products

Guideline on core SmPC for human fibrinogen products 23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation

More information

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to

More information